Bitwise’s NEAR ETF is already in the final stretch of its process: on September 24, it filed Form 8-A to register the trust shares under Section 12(b) of the Securities Exchange Act of 1934, preparing to list on NYSE Arca under the ticker NRR. The corresponding S-1 (File No. 333-286995) was filed around September 16; in an earlier version of the amendment, the parent company, Bitwise Asset Management, subscribed for the seed capital by buying 8 shares at $200 per share, i.e., $25 per share.
In the product design, there are two points that are more worth watching than “another coin packaged into an ETF.” First, the NAV is benchmarked to the New York variant of the CME CF NEAR Protocol–Dollar Reference Rate, calculated by CF Benchmarks at 16:00 New York time—i.e., putting it into a pricing framework that institutional players are already familiar with. Second, the trust explicitly will stake part of the $NEAR it holds to earn additional yield, and the staking fee is “an additional 33% of the NEAR earned”—meaning one-third of staking rewards is taken out.
My stance is straightforward: that 33% haircut determines NRR is an exposure that is “convenient but not cheap.” For accounts that can’t build their own validator infrastructure and don’t want to manage private keys, it may be the lowest-cost tier within a compliant framework; but for people who already stake on-chain, this ETF’s returns are inherently inferior to simply holding and staking the tokens directly. Don’t expect it to replace self-staking.
There are three practical things to watch: first, after the 8-A filing there typically remains a 424(b)(3) prospectus and the timing of effectiveness—this window is often when the newsflow is hottest and the price is least stable; second, after listing, the changes in NRR share balances and the premium/discount—that’s the real demand; third, the funding rate on the $NEAR perpetual contract—if ETF-related arbitrage buy pressure keeps pushing the rate down, it signals that the spot side is being drained.
As for price, NEAR saw a clear upward move after the news came out, and treating “filing the application” as the buy point is an old trap: good news is usually priced in before listing, while the real selling pressure shows up after subscriptions and redemptions are available.
How would you choose: accept the 33% staking haircut to buy NRR, or stake $NEAR yourself and take on all operational risk?
#BitwiseFilesNEARProtocolETFforListing
In the product design, there are two points that are more worth watching than “another coin packaged into an ETF.” First, the NAV is benchmarked to the New York variant of the CME CF NEAR Protocol–Dollar Reference Rate, calculated by CF Benchmarks at 16:00 New York time—i.e., putting it into a pricing framework that institutional players are already familiar with. Second, the trust explicitly will stake part of the $NEAR it holds to earn additional yield, and the staking fee is “an additional 33% of the NEAR earned”—meaning one-third of staking rewards is taken out.
My stance is straightforward: that 33% haircut determines NRR is an exposure that is “convenient but not cheap.” For accounts that can’t build their own validator infrastructure and don’t want to manage private keys, it may be the lowest-cost tier within a compliant framework; but for people who already stake on-chain, this ETF’s returns are inherently inferior to simply holding and staking the tokens directly. Don’t expect it to replace self-staking.
There are three practical things to watch: first, after the 8-A filing there typically remains a 424(b)(3) prospectus and the timing of effectiveness—this window is often when the newsflow is hottest and the price is least stable; second, after listing, the changes in NRR share balances and the premium/discount—that’s the real demand; third, the funding rate on the $NEAR perpetual contract—if ETF-related arbitrage buy pressure keeps pushing the rate down, it signals that the spot side is being drained.
As for price, NEAR saw a clear upward move after the news came out, and treating “filing the application” as the buy point is an old trap: good news is usually priced in before listing, while the real selling pressure shows up after subscriptions and redemptions are available.
How would you choose: accept the 33% staking haircut to buy NRR, or stake $NEAR yourself and take on all operational risk?
#BitwiseFilesNEARProtocolETFforListing